P3-1-21A case of treatment with afatinib + paclitaxel combination after PD treatment with afatinib in a patient with NSCLCGoto, Hiroaki; Handa, Naoko; Minakata, Kunihiko; Myojo, Tomohiro; Osawa, Hiroshi · Annals of Oncology · 2015

Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomesLu, Xiaoyan; Liu, Sha; Yang, Xiucheng; Han, Meishan; Sun, Kaoxiang · Journal of Pharmaceutical and Biomedical Analysis · 2018

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)Horn, L.; Gettinger, S.; Camidge, R.; Smit, E.; Janjigian, Y.; Pao, W.; Schnell, D.; Wang, B.; Chand, V.; Groen, H. · International Journal of Radiation Oncology*Biology*Physics · 2014

Isolation and structural characterization of degradation products of afatinib dimaleate by LC-Q-TOF/MS/MS and NMR: cytotoxicity evaluation of afatinib and isolated degradation productsChavan, Balasaheb B.; Sawant, Vitthal; Borkar, Roshan M.; Ragampeta, Srinivas; Talluri, M.V.N. Kumar · Journal of Pharmaceutical and Biomedical Analysis · 2019

Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinomaPirazzoli, V.; Ayeni, D.; Meador, C. B.; Sanganahalli, B.; Hyder, F.; de Stanchina, E.; Goldberg, S. B.; Pao, W.; Politi, K. · Clinical Cancer Research · 2015

Afatinib: First Global ApprovalDungo, Rosselle T.; Keating, Gillian M. · Drugs · 2013

L’afatinib (BIBW 2992)Prim, N.; Fore, M.; Mennecier, B. · Revue de Pneumologie Clinique · 2014